SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.

Bonelli, Michael Markus; Mrak, Daniel; Perkmann, Thomas; Haslacher, Helmuth; Aletaha, Daniel

Bonelli, Michael Markus; Mrak, Daniel; Perkmann, Thomas; Haslacher, Helmuth; Aletaha, Daniel.

Bonelli MM; Division of Rheumatology, Medical University of Vienna, Vienna, Austria.
Mrak D; Division of Rheumatology, Medical University of Vienna, Vienna, Austria.
Perkmann T; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Haslacher H; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Aletaha D; Division of Rheumatology, Medical University of Vienna, Vienna, Austria daniel.aletaha@meduniwien.ac.at.

Ann Rheum Dis ; 80(10): 1355-1356, 2021 10.

Article in English | MEDLINE | ID: covidwho-1219003

Subject(s)

COVID-19 Vaccines/immunology; COVID-19/prevention & control; Immunocompromised Host/immunology; Immunogenicity, Vaccine/drug effects; Rheumatic Diseases/immunology; Rituximab/therapeutic use; Antibodies, Viral/blood; Antibodies, Viral/immunology; Antirheumatic Agents/therapeutic use; BNT162 Vaccine; Humans; Immunity, Cellular/drug effects; Immunity, Cellular/immunology; Immunity, Humoral/drug effects; Immunity, Humoral/immunology; Immunogenicity, Vaccine/immunology; Rheumatic Diseases/drug therapy; SARS-CoV-2

Keywords

B-lymphocytes; COVID-19; rituximab

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Rheumatic Diseases / Immunocompromised Host / Rituximab / Immunogenicity, Vaccine / COVID-19 Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2021 Document Type: Article Affiliation country: Annrheumdis-2021-220408

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google